Full-Time

Global OT Partner Enablement

Posted on 5/9/2026

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

London, UK + 4 more

More locations: King of Prussia, PA, USA | Kankakee, IL, USA | Waltham, MA, USA | United States

In Person

Category
Business & Strategy (2)
,
Requirements
  • Bachelor of Science in an Engineering, Automation, Computer Science or local equivalent
  • 10+ years’ work experience, with at least 5 years’ experience in execution systems, operational technology, IT and operations
  • Specific experience in process automation, MES and batch manufacturing industry standards (ISA S88 &S95)
  • Direct experience designing, building, deploying and supporting automation and execution systems (SCADA, DCS, MES, PAT, LIMS, Digital Methods, OSI Pi Data historian, etc.) in a regulated large-scale process-based manufacturing environment
  • Experience writing, executing, and monitoring automation contract deliverables
  • Ability to work across a range of countries and cultures
  • Strong project management skills and experience in engineering projects within biopharma manufacturing
  • Functional knowledge of cGMPs and manufacturing operations in FDA-regulated facilities
  • Automation & Execution Systems Expertise
  • Project Management
  • Regulatory Compliance
  • Strategic Planning
  • Stakeholder Engagement
  • Strategic innovation
  • Delivering Enterprise Results and Value Orientation
Responsibilities
  • Establish and maintain the global governance framework for OT partners, including strategic platform providers, strategic suppliers and shared service delivery models
  • Define roles, responsibilities, and interfaces between Tier 1 partners, shared services, and internal teams to avoid overlap and gaps
  • Ensure partner governance practices (reviews, escalations, approvals) are consistently applied across all regions and sites
  • Drive adherence in collaboration with DQ and CSV to GxP, safety, and regulatory expectations in all partner-delivered services and projects
  • Design and oversee the shared services structure for OT partner-delivered services (run, maintain, enhance) across PCS, MES, OSI PI, LIMS, and related platforms
  • Define the global OT service catalog, SLAs/KPIs, and RACI for internal teams, shared services, and external partners
  • Coordinate with global and site stakeholders to ensure services are right-sized, sustainable, and cost-effective
  • Monitor service performance data and drive improvements in reliability, responsiveness, and quality of shared and partner-delivered services
  • Own and maintain global master service agreements, quality plans, service agreements, and maintenance agreements for strategic OT partners and shared services
  • Develop, standardize, and continuously improve project contracting templates for use across all OT platforms and project types
  • Partner with At-site E&M, Legal, Procurement, and functional contract owners to ensure contracts clearly define scope, deliverables, compliance, and pricing structures
  • Periodically review and refresh contract terms to reflect evolving business needs, risk posture, and partner performance
  • Oversee partner project delivery quality for OT-related operational and capital projects, ensuring adherence to global standards, templates, and governance
  • Establish expectations for partner project governance, documentation, testing, and handover to operations for all partner-led projects
  • Capture and feed partner related project lessons learned into global standards, templates, and partner governance processes
  • Ensure partner and shared service agreements support the full lifecycle of OT platforms (introduction, expansion, upgrades, decommissioning)
  • Align partner responsibilities with platform roadmaps for PCS, MES, OSI PI, LIMS, and other OT enterprise applications
  • Coordinate with OT Architecture, I&T, and platform owners to confirm lifecycle activities are contractually defined, resourced, and scheduled
  • Track execution of lifecycle activities and drive corrective actions when deviations from standards, timelines, or quality expectations occur
  • Drive adoption of the global partner and shared service model at sites, ensuring local teams understand and operate within defined roles, processes, and contracts
  • Partner with site Engineering, Automation, and Operations leaders to align local use of shared services and partners with the global model
  • Identify local exception or special cases, and work to harmonize them or formalize controlled exceptions
  • Provide coaching, communication, and change management support to reinforce the global partner and shared service strategy at the local level
  • Define and maintain enterprise KPIs, scorecards, and review cadences for strategic OT partners and shared services
  • Lead periodic performance and business reviews with partners and shared service leaders to address issues, risks, and opportunities for improvement
  • Act as the primary escalation point for structural performance concerns or contractual disputes related to OT services
  • Foster long-term, collaborative relationships with strategic partners and shared service teams that promote innovation, efficiency, and reliability across the OT ecosystem

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Simplify Jobs

Simplify's Take

What believers are saying

  • HEMGENIX gene therapy sustains 37% factor IX levels through four years post-2025 data.
  • KOSTAIVE self-amplifying mRNA COVID vaccine approved by EC February 2025.
  • VarmX $2.2B acquisition option expands bleeding disorder pipeline in 2026.

What critics are saying

  • Seqirus separation triggers $500M charges and 14% revenue loss from Pentagon mandate scrap.
  • Grifols opens 20 plasma centers by 2027, eroding CSL Behring's immunoglobulin share.
  • Novartis Fabhalta displaces CSL Vifor's $1.5B nephrology revenues within 12 months.

What makes CSL unique

  • CSL Behring leads plasma-derived therapies for haemophilia and immunodeficiencies.
  • CSL Seqirus dominates influenza vaccines with global production scale.
  • CSL Vifor specializes in iron deficiency and nephrology treatments post-2022 acquisition.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at CSL who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Company News

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

Stock Titan
Aug 1st, 2025
Automated Logic Acquires Control Solutions Ltd.

Automated Logic – Canada, Ltd. (ALC), part of Carrier Global Corporation, has acquired Control Solutions, Ltd. (CSL), an independent provider of building-automation systems in Coquitlam, British Columbia. This acquisition establishes ALC's first field office in Vancouver, expanding its presence in Western Canada and enhancing its ability to deliver intelligent building solutions in high-growth sectors across British Columbia.

PharmiWeb.com
Apr 14th, 2025
First Patient Treated With Hemgenix® (Etranacogene Dezaparvovec) Gene Therapy For Haemophilia B In Austria

Vienna, Austria – 9 April 2025 - CSL Behring Austria today announced that the first haemophilia B patient in Austria was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Comprehensive Care Center of the University Hospital of Medicine Vienna.HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1“It is a great opportunity for people with hemophilia B to live a symptom-free life for many years,” explains hematologist Univ.-Prof. Priv.-Doz. Dr Cihan Ay from the Medical University of Vienna, University Clinic for Internal Medicine I Clinical Department for Hematology and Hemostaseology."For the community of affected patients and their families, this represents an enormously significant milestone: the ability to treat hemophilia with gene therapy, and the fact that this option is now available in Austria, is something our community has been eagerly anticipating and hoping for over decades," says Thomas Schindl, MA, Chairman of the Austrian Hemophilia Society (ÖHG)."We are proud and grateful to offer haemophilia B patients in Austria a treatment option that has the potential to transform their lives," said Dr Beate Natmessnig, Managing Director of CSL Behring Austria. "This achievement is the result of outstanding regional and national collaboration among all parties involved and is a strong testament to Austria's innovative capabilities."HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022

PharmiWeb.com
Apr 3rd, 2025
Csl Behring And Gkv-Spitzenverband Agree On Reimbursement Price For Hemgenix® – Europe'S First Gene Therapy For Haemophilia B

Marburg, Germany, 2 April 2025 – CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX®. This agreement marks the availability of the first gene therapy approved in Europe for haemophilia B under an innovative, national, success-based reimbursement model, being implemented for the first time in Germany.HEMGENIX® represents significant progress in the treatment of haemophilia B. The aim of this one-time gene therapy is to eliminate the need for regular factor IX infusions, thereby offering patients the possibility of more freedom from prophylaxis and significantly improving their quality of life.1-4 This development not only provides substantial relief for those affected but also has the potential to reduce long-term costs for the healthcare system.‘The performance-based payment model at national level which was agreed with the GKV-Spitzenverband is unique in Germany. It addresses key reimbursement challenges, such as the question of long-term efficacy, which is inherent for any one-time therapy. Reimbursement is linked to treatment success of the individual patient,’ explains Stefan Neudoerfer, CSL Behring's chief negotiator in Germany.Moreover, this reimbursement model reflects the high therapeutic and innovative value of HEMGENIX® and sets new standards for integrating innovative gene therapies into the German healthcare system.‘The agreement on the reimbursement price of HEMGENIX® is a decisive step for the care of people with haemophilia B in Germany. It enables access to a groundbreaking therapy and recognises the long-term medical and economic benefits of gene therapy,’ explains Christian Wieszner, Managing Director of CSL Behring Germany.With this agreement, CSL Behring is underlining its commitment to innovative therapies that sustainably improve the lives of patients